MARKET

VIRX

VIRX

Viracta Therapeutics Inc
NASDAQ
0.1667
-0.0022
-1.30%
After Hours: 0.1693 +0.0026 +1.56% 19:53 01/21 EST
OPEN
0.1772
PREV CLOSE
0.1689
HIGH
0.1772
LOW
0.1579
VOLUME
499.01K
TURNOVER
--
52 WEEK HIGH
1.310
52 WEEK LOW
0.1315
MARKET CAP
6.63M
P/E (TTM)
-0.1511
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VIRX last week (0113-0117)?
Weekly Report · 2d ago
Weekly Report: what happened at VIRX last week (0106-0110)?
Weekly Report · 01/13 09:25
Weekly Report: what happened at VIRX last week (1230-0103)?
Weekly Report · 01/06 09:27
Weekly Report: what happened at VIRX last week (1223-1227)?
Weekly Report · 12/30/2024 09:25
Stocks Set to Open Lower as Investors Trim Risk Amid Year-End Uncertainty
Barchart · 12/30/2024 04:44
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 12/27/2024 21:05
Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues
Benzinga · 12/27/2024 20:44
ServiceTitan initiated, Viracta downgraded: Wall Street’s top analyst calls
TipRanks · 12/27/2024 14:35
More
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Webull offers Viracta Therapeutics Inc stock information, including NASDAQ: VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.